Merck: big in Japan
(CercleFinance.com) - Merck has simultaneously won five new approvals from Japan's health regulators for its immunotherapy Keytruda, including three expanded uses in advanced non-small lung cancer, the drugmaker said on Thursday.
Merck's anti-PD-1 therapy has also been approved in melanoma, the company said, as well as a new indication in advanced microsatellite instability-high tumors.
This Thursday Merck also said that it has decided to exercise its option to license an investigational monoclonal antibody from partner NGM that is currently being evaluated for the treatment of nonalcoholic steatohepatitis (NASH) and type-2 diabetes, as part of the companies' strategic collaboration.
Copyright (c) 2019 CercleFinance.com. All rights reserved.
Merck's anti-PD-1 therapy has also been approved in melanoma, the company said, as well as a new indication in advanced microsatellite instability-high tumors.
This Thursday Merck also said that it has decided to exercise its option to license an investigational monoclonal antibody from partner NGM that is currently being evaluated for the treatment of nonalcoholic steatohepatitis (NASH) and type-2 diabetes, as part of the companies' strategic collaboration.
Copyright (c) 2019 CercleFinance.com. All rights reserved.